


p.i.o

Ergebnisse aus Qualitätssicherungsprojekten Mammakarzinom

Jahrestagung 2010


Berlin

> 16.000 Patienten in p.i.o.-Projekten
5.654 mit Mammakarzinom




Mammakazinom

5363 Pat. gemeldet



Mammakazinom

primär systemische Therapie



Präoperative Therapie des Mammakarzinoms

Komplette Remissionen (n=33)

Therapie	n	pCR
AC/EC-Docetaxel	109	21 (19%)
AC/EC-Paclitaxel*	63	8 (13%)
DAC/DEC	42	7 (17%)

*Therapie alle 21 Tage

p.i.o

Präoperative Therapie des Mammakarzinoms

Komplette Remissionen

Response	n = 217
pCR	36 (17%)

Study	pCR
AGO	13%
Geparduo	16%
NSABP-B27	17%

n = 8 not evaluable (no operation)

p.i.o

Präoperative Therapie des Mammakarzinoms

Komplette Remissionen

Response	n = 217
pCR	36 (17%)
pPR	134 (62%)
pNC	39 (18%)
pPD	8 (4%)

Study	pCR
AGO	13%
Geparduo	16%
NSABP-B27	17%


n = 8 not evaluable (no operation)

p.i.o

Präoperative Therapie des Mammakarzinoms

Risikofaktoren


(n=219)



Präoperative Therapie des Mammakarzinoms


Risikofaktoren und komplette Remissionen

(n=33)




Präoperative Therapie des Mammakarzinoms

pCR nach Histologie



Präoperative Therapie des Mammakarzinoms

pCR und Alter




n = 219

p.i.o

Präoperative Therapie des Mammakarzinoms

Krankheitsfreies Überleben postoperativ



2 Jahres-Follow up:

n = 120

3 Jahres-Follow up:

n = 65

11 Lokalrezidive

33 Fernmetastasierungen


2 Zweitneoplasie

25 verstorben

p.i.o


Präoperative Therapie des Mammakarzinoms

Gesamtüberleben



Mammakarzinom


Adjuvante Chemotherapie



Mammakarzinom

Adjuvante Chemotherapie


T-Stadien



Mammakarzinom

Adjuvante Chemotherapie


N-Stadien




Mammakarzinom

Adjuvante Chemotherapie

Grading



Mammakarzinom
Adjuvante Therapie
Her2neu-Status (n = 1.916)



Mammakarzinom

Adjuvante Immuntherapie


Her2neu-Status	n	Immuntherapie*
Her2neu-positiv	434	365 (84,1%)

*Trastuzumab, Lapatinib oder beides,
Trastuzumab-Zulassung erst Mai 2006

Mammakarzinom

Adjuvante Therapie

Krankheitsfreies Überleben ab OP



Patienten mit Kontaktverlust nicht berücksichtigt

1626 Patienten

40 Death

17 Lokalrezidive

70 Fernmetastasierungen

6 Zweitneoplasien

p.i.o

Mammakarzinom


Adjuvante Chemotherapie

Regime	Zyklen (geplant)	auswertbare Patienten
FEC	6	775 (40%)
FEC-Docetaxel	6	676 (35%)
EC-Paclitaxel	8	124 (6%)
DAC	6	94 (5%)
EC-Docetaxel	8	92 (5%)
Andere		155 (8%)
Gesamt		1.916 (100%)

p.i.o


Mammakarzinom - Adjuvante Chemotherapie

Mukositis (pro Patient)




Mammakarzinom - Adjuvante Chemotherapie

Leukopenie




Mammakarzinom - Adjuvante Chemotherapie

G-CSF Gabe




Mammakarzinom - Adjuvante Chemotherapie

Begleitmedikation




Mammakarzinom - Adjuvante Chemotherapie

Stationäre Aufnahme




Mammakarzinom - Adjuvante Chemotherapie

Therapieverschiebungen ≥ 1 Woche




Mammakarzinom - Adjuvante Chemotherapie

Dosisreduktionen




Mammakarzinom - adjuvante Chemotherapie

Dosis-Intensität




Mammakarzinom - Adjuvante Chemotherapie

Antiemese




Mammakazinom Stad. IV 5363 Pat. gemeldet

1716
Pat.



Metastasiertes Mammakarzinom

palliative Chemotherapie-Linien




n = 666 (61%) verstorben (vollständiges Follow up)

p.i.o

Metastasiertes Mammakarzinom

Chemotherapie - Objektive Remissionsraten



1086 Pat, davon = 666 (61%) verstorben (vollständiges Follow up) p.i.o

Metastasiertes Mammakarzinom

Chemotherapie - Linien

Remissionsdauer bei CR/PR in Monaten




Metastasiertes Mammakarzinom

Chemotherapie - Linien


998 Pat. (3.2.2010)

■ Kombinationstherapie ■ Monotherapie




Metastasiertes Mammakarzinom

Medianes Überleben nach Erstmetastasierung




Metastasiertes Mammakarzinom

Chemotherapie 1st-line – medianes Überleben



Metastasiertes Mammakarzinom


Chemotherapien: Substanzklassen




Metastasiertes Mammakarzinom

1st-line-Chemotherapie

Medianes Überleben ab Therapiebeginn



Metastasiertes Mammakarzinom




Docetaxel/Epirubicin
1st-line

n = 76

Medianes Überleben
ab Therapiebeginn
22,8 Monate

p.i.o

Metastasiertes Mammakarzinom



Capecitabin
2nd-line


n = 53

Medianes Überleben
ab Therapiebeginn
16,0 Monate

p.i.o

Metastasiertes Mammakarzinom

Hormontherapien: Substanzklassen



Metastasiertes Mammakarzinom

palliative Hormontherapie


mediane Therapiedauer in Tagen



Metastasiertes Mammakarzinom


endokrine Therapie 1st-line

Mediane Überlebenszeit



Metastasiertes Mammakarzinom

Medianes Überleben ab Therapiebeginn 1st-line



Metastasiertes Mammakarzinom

Medianes Überleben ab Therapiebeginn 1st-line

